Are GMP Violations The “Next Hot Thing” In False Claims Act Litigation?
Executive Summary
Former prosecutors say there are cases pending under seal, but it is uncertain whether the government will intervene. They note the difficulty in proving the allegations and say FDA’s regulatory regime may be a better route for handling GMP issues.
You may also be interested in...
DoJ and GMPs: A Prosecutor’s Take on Enforcing Product Quality
The wave of marketing promotions undertaken by the Department of Justice over the past decade may be abating, but prosecutors are looking at manufacturing violations as fertile new territory for cases. One prosecutor shares her thoughts on how companies can protect themselves.
GSK’s $750 Mil. DoJ Settlement: When GMP Violations Equal Healthcare Fraud
GlaxoSmithKline’s $750 million settlement with the Department of Justice raises a worrisome question for industry: will violations of current good manufacturing practices become a target for whistleblower suits?
FTC May Be Hampered In Pursuing Actions Against Pharma In Wake Of Supreme Court Ruling
High court’s decision that FTC lacks authority to seek monetary recovery in litigation is boon for drug makers who have been subject to hefty payouts in reverse settlement and other cases brought by the commission.